Pfizer Tests The Luck Of The Irish; Will The US Let Its Pharma Pot Of Gold Go?
Executive Summary
Pfizer and Allergan confirmed they are in friendly merger negotiations. Now the question is if Pfizer can afford to pay for Allergan and will the US government let a pharma giant the size of Pfizer go without a fight.
You may also be interested in...
Actavis’ Big Bet On Diversified Hybrid Model Reflects Industry Trends
Actavis’ proposal to buy Forest Labs for $25 billion in stock and cash was driven by consolidating customers and fierce competition in traditional Western markets. Different pressures, namely the tough-to-manage patent cliff, as well as leadership succession issues and investor unrest, drove Forest into the arms of a suitor.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.